Minaris Advanced Testing

Advanced biologics—including monoclonal antibodies (mAbs), recombinant proteins, viral vaccines, and cell and gene therapies—hold immense promise for treating and preventing a wide range of diseases. Ensuring the safety, purity, and efficacy of these complex products requires robust, stage-appropriate testing throughout the entire development lifecycle, from early research to commercialization. Minaris Advanced Testing is a trusted partner in this journey, offering a comprehensive suite of integrated biosafety and characterization services designed to streamline development timelines and support regulatory success across diverse therapeutic modalities.

While each product class presents distinct challenges, they share a common need for rigorous molecular, microbiological, and viral safety testing. Cell and gene therapies often involve inherent biological variability and limited sample volumes. mAbs and recombinant proteins require thorough viral clearance validation, impurity testing, and stability assessment. Vaccines demand extensive viral safety and adventitious agent testing to ensure patient safety at scale. Minaris Advanced Testing brings more than 40 years of experience addressing these complexities with scientific rigor and regulatory insight.

Beyond core biosafety testing, Minaris Advanced Testing offers deep expertise in assay development, potency testing, stability studies, viral clearance, and cell line characterization—capabilities that support both established biologics platforms and emerging advanced therapies. Their newly constructed, purpose-built, state-of-the-art facility in Philadelphia, Pennsylvania, provides a modern testing environment designed to deliver reliable, coordinated services through a streamlined, client-focused approach.